Skip to content

Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study

Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02756468
Acronym
PREDIPS
Enrollment
100
Registered
2016-04-29
Start date
2015-01-31
Completion date
2016-12-31
Last updated
2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

pancreatic cancer, procalcitonin

Brief summary

Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC). Purpose. The investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after pancreatic surgery

Interventions

OTHERpts operated for pancreatic cancer

measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* patients undergoing all different kinds of pancreatic surgery * in elective setting * for cancer * with a pancreatic anastomosis performed.

Exclusion criteria

* age \< 18 years * pregnant women * patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery2 yrsSensitivity: % of patients corrected identified by the biomarkers having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak
Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery2 yrsSpecificity: % of pts corrected identified by the biomarkers not having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak

Secondary

MeasureTime frameDescription
PCT and CRP cuts-off in 3rd POD with a good NPV for AL2 yrsPCT: procalcitonin, CRP: C-reactive protein, NPV: negative predictive value
PCT and CRP cuts-off in 5th POD with a good NPV for AL2 yrsPCT: procalcitonin, CRP: C-reactive protein, NPV: negative predictive value

Countries

Italy

Contacts

Primary ContactValentina Giaccaglia, MD
v.giaccaglia@gmail.com+393397882429

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026